Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd., Highlighting Strategic Pipeline Expansion

Stonegate Capital Partners has initiated coverage on Medicus Pharma Ltd. (NASDAQ: MDCX), highlighting the company's strategic initiatives during the second quarter of 2025. Medicus advanced several key developments as it builds a diversified portfolio of clinical and pre-clinical assets. The company completed the acquisition of Antev Limited, expanding its therapeutic pipeline into dermatology and infectious diseases, which complements its lead microneedle patch technology for skin cancer treatment. This acquisition represents a significant step in Medicus's strategy to broaden its therapeutic focus beyond its core oncology programs.

In addition to the Antev acquisition, Medicus entered into a Memorandum of Understanding with Helix Nanotechnologies to co-develop thermostable vaccines for infectious diseases. This collaboration addresses critical global healthcare challenges tied to cold-chain limitations, particularly relevant for vaccine distribution in developing countries and remote areas. The partnership leverages Helix's nanotechnology expertise to create vaccines that can maintain stability without refrigeration, potentially revolutionizing vaccine delivery systems worldwide. Further details about this strategic partnership can be found in the company's official announcements at https://www.medicuspharma.com/partnerships.

Financially, Medicus secured an $8.0 million non-dilutive debenture financing during the quarter, strengthening its balance sheet and extending its cash runway while minimizing dilution for existing shareholders. The company reported a net loss of $6.2 million for the second quarter of 2025, compared to $3.6 million in the same period last year, reflecting increased expenses of $4.6 million and research and development investment of $1.4 million. For the six-month period, the net loss widened to $11.3 million versus $5.3 million in the prior year, consistent with the company's expanded development and corporate activities.

Cash and equivalents stood at $9.7 million at quarter-end, an increase from $4.2 million at year-end 2024, supported by equity raises, warrant exercises, and $4.5 million in proceeds from the debenture issuance. Management expects that recent financings, combined with disciplined cost control, will provide sufficient capital to advance ongoing clinical and business development programs into 2026. The company's financial reports and SEC filings are available at https://www.sec.gov/edgar/search.

Medicus's lead program, SkinJect, is a dissolvable microneedle patch designed for localized delivery of chemotherapeutic agents to treat non-melanoma skin cancers, including basal cell carcinoma. The product is intended for outpatient use, potentially reducing treatment costs and improving compliance relative to surgical and systemic approaches. The Antev acquisition further expands Medicus's portfolio into dermatology and infectious disease assets, while the Helix Nanotechnologies collaboration introduces vaccine development capabilities with a focus on thermostable platforms. Information about SkinJect's clinical development can be accessed through clinical trial databases at https://clinicaltrials.gov.

Stonegate Capital Partners used a probability-adjusted Discounted Cash Flow Model when valuing MDCX, returning a valuation range of $14.91 to $29.35 with a midpoint of $21.13 based on a discount rate range of 17.50% to 22.50% and a current risk adjustment range of 50% to 40%. The valuation model is highly leveraged to future years due to the long-term nature of Medicus's industry, leading to potential for significant re-ratings as new information becomes available. These milestones have highlighted the company's strategy of combining organic development with opportunistic acquisitions to accelerate the advancement of its therapeutic assets.